Literature DB >> 750108

Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil in a variety of mouse tumors.

M Iigo, A Hoshi, A Nakamura, K Kuretani.   

Abstract

The antitumor properties of 1-alkylcarbamoyl derivatives of 5-fluorouracil were examined in various mouse tumor systems to select promising compounds for clinical use. Almost all alkylcarbamoyl derivatives were active against various tumors when given by oral administration. Among them, 1-methyl, 1-ethyl, 1-isopropyl, 1-hexyl and 1-octyl carbamoyl derivatives of 5-fluorouracil were moderately or markedly active in six mouse tumor systems tested. However, 1-methyl, 1-ethyl, and 1-isopropyl carbamoyl derivatives were toxic to mice, though not lethal. As a result, 1-hexyl and 1-octyl carbamoyl derivatives were selected as the best candidates for antitumor agents in further study.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 750108     DOI: 10.1007/bf00257150

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

Review 1.  The clinical impact of screening and other experimental tumor studies.

Authors:  R K Johnson; A Goldin
Journal:  Cancer Treat Rev       Date:  1975-03       Impact factor: 12.111

Review 2.  QUANTITATIVE CONCEPTS IN THE CLINICAL STUDY OF DRUGS.

Authors:  C G ZUBROD
Journal:  Adv Chemother       Date:  1964

3.  Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil.

Authors:  H Toide; H Akiyoshi; Y Minato; H Okuda; S Fujii
Journal:  Gan       Date:  1977-10

4.  Antitumor activity of benzoyl and benzenesulfonyl derivatives of 5-fluorouracil.

Authors:  A Hoshi; M Iigo; N Nakamura; K Kuretani
Journal:  Gan       Date:  1974-10

5.  A double-blind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinoma.

Authors:  R G Hahn; C G Moertel; A J Schutt; H W Bruckner
Journal:  Cancer       Date:  1975-04       Impact factor: 6.860

6.  Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil against L1210 leukemia.

Authors:  A Hoshi; M Iigo; A Nakamura; M Inomata; K Kuretani
Journal:  Chem Pharm Bull (Tokyo)       Date:  1978-01       Impact factor: 1.645

7.  Antitumor activity of carbamoyl derivatives of 5-fluorouracil by oral administration.

Authors:  A Hoshi; M Iigo; M Yoshida; K Kuretani
Journal:  Gan       Date:  1975-12
  7 in total
  6 in total

1.  Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with L-cystine.

Authors:  M Iigo; A Hoshi; H Kitagawa
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

2.  White light-mediated Cu (II)-5FU interaction augments the chemotherapeutic potential of 5-FU: an in vitro study.

Authors:  Sandesh Chibber; Mohd Farhan; Iftekhar Hassan; Imrana Naseem
Journal:  Tumour Biol       Date:  2011-05-27

Review 3.  Subacute leucoencephalopathy induced by carmofur, a 5-fluorouracil derivative.

Authors:  S Kuzuhara; N Ohkoshi; K Kanemaru; H Hashimoto; T Nakanishi; Y Toyokura
Journal:  J Neurol       Date:  1987-08       Impact factor: 4.849

4.  Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil.

Authors:  T Tsuruo; H Iida; K Naganuma; S Tsukagoshi; Y Sakurai
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

5.  Pharmacokinetics of 1-alkylcarbamoyl-5-fluorouracils in plasma and ascites fluid after oral administration in mice.

Authors:  M Iigo; A Hoshi; K Kuretani
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 6.  Radiation- and photo-induced activation of 5-fluorouracil prodrugs as a strategy for the selective treatment of solid tumors.

Authors:  Takeo Ito; Kazuhito Tanabe; Hisatsugu Yamada; Hiroshi Hatta; Sei-ichi Nishimoto
Journal:  Molecules       Date:  2008-10-01       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.